<unk> , sold under the brand name Rethymic, is a<unk>  tissue medical therapy used for the treatment of children with congenital athymia. It takes six months or longer to reconstitute the immune function in treated people. The most common adverse reactions include high blood pressure, cytokine release syndrome, low blood magnesium levels, rash, low platelets, and graft versus host disease. It was approved for medical use in the United States in October 2021.<unk>  is the first<unk>  tissue product approved by the U.S. Food and Drug Administration (FDA).<unk>  is composed of human<unk>  (donor-derived)<unk>  tissue that is<unk>  and cultured, and then implanted into people to help reconstitute immunity (improve immune function) in people who are athymic. Dosing is patient customized, determined by the surface area of the<unk>  slices and the body surface area of the patient.
Allogeneic processed thymus tissue
Patient derived xenograft
Circulating tumor cell
Vaccine-induced seropositivity
Minimally manipulated cells
Transplantable organs and tissues
Isograft
Autologous patient-specific tumor antigen response